ApoGen Receives $7 Million Investment for Cancer Therapy
ApoGen Biotechnologies Inc., a U of M startup, announced last month that it had received $7 million from life science investment firm Accelerator Corporation to continue developing a new class of drugs that slows the evolution of cancer cells.